WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406180
CAS#: 101622-51-9
Description: Olomoucine is a CDK inhibitor that competes for the ATP binding site of the kinase. Olomoucine was shown to reversibly arrest differentiated Petunia cells induced to divide at G1 phase and cycling Arabidopsis cells in late G1 and G2.
MedKoo Cat#: 406180
Name: Olomoucine
CAS#: 101622-51-9
Chemical Formula: C15H18N6O
Exact Mass: 298.15421
Molecular Weight: 298.34
Elemental Analysis: C, 60.39; H, 6.08; N, 28.17; O, 5.36
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Olomoucine
IUPAC/Chemical Name: 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine
InChi Key: GTVPOLSIJWJJNY-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20)
SMILES Code: CN1C=NC2=C(NCC3=CC=CC=C3)N=C(NCCO)N=C12
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 298.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, Staud F. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res. 2012 Mar;65(3):312-9. doi: 10.1016/j.phrs.2011.11.017. Epub 2011 Dec 6. PubMed PMID: 22173067.
2: Korinkova G, Cwiertka K, Paprskarova M, Dzubak P, Hajduch M. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors. Neoplasma. 2010;57(2):161-9. PubMed PMID: 20099981.
3: Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B. The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother. 2010 Jan 5;20(3):133-42. doi: 10.3851/IMP1460. PubMed PMID: 20054100; PubMed Central PMCID: PMC2948526.
4: Małecki JM, Bentke A, Ostrowska B, Laidler P. Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis. Melanoma Res. 2010 Feb;20(1):52-8. doi: 10.1097/CMR.0b013e328332f1e6. PubMed PMID: 20010439.
5: Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Ann N Y Acad Sci. 2009 Aug;1171:242-9. doi: 10.1111/j.1749-6632.2009.04700.x. PubMed PMID: 19723061.
6: Fei XF, Qin ZH, Xiang B, Li LY, Han F, Fukunaga K, Liang ZQ. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Res. 2009 Apr 6;1264:85-97. doi: 10.1016/j.brainres.2009.01.057. Epub 2009 Feb 6. PubMed PMID: 19368812.
7: Siller M, Anzenbacher P, Anzenbacherova E, Dolezal K, Popa I, Strnad M. Interactions of olomoucine II with human liver microsomal cytochromes P450. Drug Metab Dispos. 2009 Jun;37(6):1198-202. doi: 10.1124/dmd.108.025502. Epub 2009 Feb 27. PubMed PMID: 19251823.
8: Jhou RS, Sun KH, Sun GH, Wang HH, Chang CI, Huang HC, Lu SY, Tang SJ. Inhibition of cyclin-dependent kinases by olomoucine and roscovitine reduces lipopolysaccharide-induced inflammatory responses via down-regulation of nuclear factor kappaB. Cell Prolif. 2009 Apr;42(2):141-9. doi: 10.1111/j.1365-2184.2009.00584.x. Epub 2009 Feb 24. PubMed PMID: 19250292.
9: Tripathi BK, Stepp MA, Gao CY, Zelenka PS. The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo. Mol Vis. 2008 Mar 17;14:542-9. PubMed PMID: 18385789; PubMed Central PMCID: PMC2274924.
10: Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem. 2007 Dec 15;102(6):1405-19. PubMed PMID: 17975794.
